Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bevacizumab and Erlotinib First-Line Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer (Stage IIIB/IV) Followed by Platinum-Based Chemotherapy at Disease Progression. A Multicenter Phase II Trial

NCT00354549 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT00354549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00354549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bevacizumab and Erlotinib First-Line Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer (Stage IIIB/IV) Followed by Platinum-Based Chemotherapy at Disease Progression. A Multicenter Phase II Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2006
Completion date
September 30, 2010
Enrollment
104 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer